Cargando…

Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types

BACKGROUND: microRNAs (miRNAs) stably exist in circulating blood encapsulated in extracellular vesicles such as exosomes; therefore, serum miRNAs have the potential to serve as novel cancer biomarkers. New diagnostic markers to detect high grade serous ovarian cancer (HGSOC) are urgently needed. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Masaki, Sawada, Kenjiro, Nakamura, Koji, Yoshimura, Akihiko, Miyamoto, Mayuko, Shimizu, Aasa, Ishida, Kyoso, Nakatsuka, Erika, Kodama, Michiko, Hashimoto, Kae, Mabuchi, Seiji, Kimura, Tadashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138886/ https://www.ncbi.nlm.nih.gov/pubmed/30219071 http://dx.doi.org/10.1186/s13048-018-0458-0

Ejemplares similares

Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression
por: Nakamura, Koji, et al.
Publicado: (2019)

Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells
por: Yoshimura, Akihiko, et al.
Publicado: (2018)

Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells
por: Miyamoto, Mayuko, et al.
Publicado: (2020)

Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
por: Toda, Aska, et al.
Publicado: (2017)

Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
por: Kobayashi, Masaki, et al.
Publicado: (2020)

Effect of Japanese Kampo Medicine Therapy for Menopausal Symptoms after Treatment of Gynecological Malignancy
por: Yoshimura, Akihiko, et al.
Publicado: (2018)

Safety and efficacy of Ninjin’yoeito along with iron supplementation therapy for preoperative anemia, fatigue, and anxiety in patients with gynecological disease: an open-label, single-center, randomized phase-II trial
por: Yagi, Taro, et al.
Publicado: (2022)

Identification of Malignant Cell Populations Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer Using Single-Cell RNA Sequencing
por: Sumitani, Naoki, et al.
Publicado: (2022)

Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination
por: Nakatsuka, Erika, et al.
Publicado: (2017)

Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study)
por: Oride, Tadashi, et al.
Publicado: (2023)

The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma
por: Kinose, Yasuto, et al.
Publicado: (2015)

Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer
por: Shimura, Kotaro, et al.
Publicado: (2021)

Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer
por: Kuroda, Hiromasa, et al.
Publicado: (2018)

Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models
por: Kozasa, Katsumi, et al.
Publicado: (2019)

Role of the Exosome in Ovarian Cancer Progression and Its Potential as a Therapeutic Target
por: Nakamura, Koji, et al.
Publicado: (2019)

Clinical relevance of circulating cell-free microRNAs in ovarian cancer
por: Nakamura, Koji, et al.
Publicado: (2016)

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary
por: Takahashi, Ryoko, et al.
Publicado: (2016)

Pathophysiological Role and Potential Therapeutic Exploitation of Exosomes in Ovarian Cancer
por: Shimizu, Aasa, et al.
Publicado: (2020)

The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer
por: Kawano, Mahiru, et al.
Publicado: (2015)

Interleukin 6 Receptor Is an Independent Prognostic Factor and a Potential Therapeutic Target of Ovarian Cancer
por: Isobe, Aki, et al.
Publicado: (2015)

Gastric-Type Adenocarcinoma of the Uterine Cervix Associated with Poor Response to Definitive Radiotherapy
por: Kuruma, Airi, et al.
Publicado: (2022)

Laparoscopic spacer placement for bulky lymph node metastasis of cervical cancer: A case report
por: Kuruma, Airi, et al.
Publicado: (2022)

Benefits of Laparoscopic Surgery for Bleeding Events in Patients with Implantable Left Ventricular Assist Devices during Antithrombotic Therapy
por: Nakae, Aya, et al.
Publicado: (2022)

A single institution’s experience with minimally invasive surgery for ovarian cancer, and a systematic meta-analysis of the literature
por: Kamei, Yuji, et al.
Publicado: (2023)

Evidence for a non-strange meson of mass 1290 MeV
por: D'Andlau, C, et al.
Publicado: (1965)

An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential
por: Guz, Małgorzata, et al.
Publicado: (2022)

Circulating Exosomal miR-1290 for Diagnosis of Epithelial Ovarian Cancer
por: Jeon, Hyeji, et al.
Publicado: (2022)

Significance of the Number and the Location of Metastatic Lymph Nodes in Locally Recurrent or Persistent Cervical Cancer Patients Treated with Salvage Hysterectomy plus Lymphadenectomy
por: Mabuchi, Seiji, et al.
Publicado: (2022)

Structure within the R(1675) boson and possible structure within the A(1290)
por: Levrat, B, et al.
Publicado: (1966)

1290. A Model for “At-Distance” PrEP Navigation: Acceptability and Early Insights
por: Perlson, Jacob, et al.
Publicado: (2018)

Serum Exosomal miR-1290 is a Potential Biomarker for Lung Adenocarcinoma
por: Wu, Yining, et al.
Publicado: (2020)

A Review on the Role of miR-1290 in Cell Proliferation, Apoptosis and Invasion
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2021)

1290. Impact of Implementing an IV to PO Antibiotic Treatment Protocol for Orthopedic Infections
por: Gray, Julie, et al.
Publicado: (2023)

Novel Role for miR-1290 in Host Species Specificity of Influenza A Virus
por: Huang, Sheng-Yu, et al.
Publicado: (2019)

miR-1290 inhibits chordoma cell proliferation and invasion by targeting Robo1
por: Wang, Bin, et al.
Publicado: (2019)

1290. Ceftazidime-Avibactam Resistance Report in a Third Level Hospital in Mexico City
por: Molina, Aaron, et al.
Publicado: (2021)

miR-1290 promotes lung adenocarcinoma cell proliferation and invasion by targeting SOCS4
por: Xiao, Xuelian, et al.
Publicado: (2018)

Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer
por: Tavano, Francesca, et al.
Publicado: (2018)

Finished Genome Sequence of the Indole-3-Acetic Acid-Catabolizing Bacterium Pseudomonas putida 1290
por: Laird, Tyler S., et al.
Publicado: (2019)

miR-1290 Contributes to Colorectal Cancer Cell Proliferation by Targeting INPP4B
por: Ma, Qingzhu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d39fmm90ojmk7jv164ekfg6517